Behavioral and psychiatric symptoms in prion disease

American Journal of Psychiatry

Volumn 171, Issue 3, 2014, Pages 265-274

  Thompson, Andrew ^a   MacKay, Angus ^b   Rudge, Peter ^c   Lukic, Ana ^d   Porter, Marie Claire ^d   Lowe, Jessica ^d   Collinge, John ^d   Mead Dr , Simon ^d  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b Argyll & Bute Hospital   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CHLORPROMAZINE; CHOLINESTERASE INHIBITOR; MEPACRINE; NEUROLEPTIC AGENT; QUETIAPINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ABSENCE OF SIDE EFFECTS; AGE DISTRIBUTION; AGITATION; ARTICLE; BEHAVIOR DISORDER; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); CREUTZFELDT JAKOB DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; FOLLOW UP; GENETIC VARIABILITY; HALLUCINATION; HEADACHE; HUMAN; MENTAL DISEASE; MOOD DISORDER; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PHENOMENOLOGY; PREVALENCE; PRION DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOSIS; RISK BENEFIT ANALYSIS; SEDATION; SUICIDAL IDEATION; TASTE DISORDER; TREATMENT DURATION; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

HUMANS; MOOD DISORDERS; PRION DISEASES; PSYCHOMOTOR AGITATION; PSYCHOTIC DISORDERS; PSYCHOTROPIC DRUGS;

EID: 84898716962     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2013.12111460     Document Type: Article

References (31)

1. Collinge J: Prion diseases of humans and animals: their causes and molecular basis. Ann Rev Neurosci 2001; 24:519-550 (Pubitemid 32695238)
2. Pocchiari M, Puopolo M, Croes EA, Budka H, Gelpi E, Collins S, Lewis V, Sutcliffe T, Guilivi A, Delasnerie-Laupretre N, Brandel JP, Alperovitch A, Zerr I, Poser S, Kretzschmar HA, Ladogana A, Rietvald I, Mitrova E, Martinez-Martin P, de Pedro-Cuesta J, Glatzel M, Aguzzi A, Cooper S, Mackenzie J, van Duijn CM, Will RG: Predictors of survival in sporadic Creutzfeldt-Jakob disease and other human transmissible spongiform encephalopathies. Brain 2004; 127(Pt 10):2348-2359 (Pubitemid 39382243)
3. Kirschbaum WR: Jakob-Creutzfeldt Disease. New York, Elsevier, 1968
4. Zeidler M, Johnstone EC, Bamber RWK, Dickens CM, Fisher CJ, Francis AF, Goldbeck R, Higgo R, Johnson-Sabine EC, Lodge GJ, McGarry P, Mitchell S, Tarlo L, Turner M, Ryley P, Will RG: New variant Creutzfeldt-Jakob disease: psychiatric features. Lancet 1997; 350:908-910 (Pubitemid 27420526)
5. Spencer MD, Knight RS, Will RG: First hundred cases of variant Creutzfeldt-Jakob disease: retrospective case note review of early psychiatric and neurological features. BMJ 2002; 324:1479-1482 (Pubitemid 34666613)
6. World Health Organization: The Revision of the Surveillance Case Definition for Variant Crequtzfeldt-Jakob Disease (vCJD): Report of a WHO Consultation. Edinburgh, World Health Organization, Department of Communicable Disease Surveillance and Response, May 17, 2001 (http://whqlibdoc.who.int/hq/ 2002/WHO-CDS-CSR-EPH-2001.5.pdf)
7. Heath CA, Cooper SA, Murray K, Lowman A, Henry C, MacLeod MA, Stewart GE, Zeidler M, MacKenzie JM, Ironside JW, Summers DM, Knight RS, Will RG: Validation of diagnostic criteria for variant Creutzfeldt-Jakob disease. Ann Neurol 2010; 67:761- 770
8. Wall CA, Rummans TA, Aksamit AJ, Krahn LE, Pankratz VS: Psychiatric manifestations of Creutzfeldt-Jakob disease: a 25- year analysis. J Neuropsychiatry Clin Neurosci 2005; 17:489-495 (Pubitemid 41790049)
9. Appleby BS, Appleby KK, Crain BJ, Onyike CU, Wallin MT, Rabins PV: Characteristics of established and proposed sporadic Creutzfeldt-Jakob disease variants. Arch Neurol 2009; 66:208-215
10. Appleby BS, Appleby KK, Rabins PV: Does the presentation of Creutzfeldt-Jakob disease vary by age or presumed etiology? A meta-analysis of the past 10 years. J Neuropsychiatry Clin Neurosci 2007; 19:428-435 (Pubitemid 350156101)
11. Korth C, May BC, Cohen FE, Prusiner SB: Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci USA 2001; 98:9836-9841 (Pubitemid 32769390)
12. Appleby BS: Psychotropic medications and the treatment of human prion diseases. CNS Neurol Disord Drug Targets 2009; 8: 353-362
13. Arruda WO, Bordignon KC, Milano JB, Ramina R: [Creutzfeldt- Jakob disease, Heidenhain variant: case report with MRI (DWI) findings.] Arq Neuropsiquiatr 2004; 62:347-352 (Portuguese) (Pubitemid 38715325)
14. Benito-León J: Combined quinacrine and chlorpromazine therapy in fatal familial insomnia. Clin Neuropharmacol 2004; 27: 201-203 (Pubitemid 39121736)
15. Martínez-Lage JF, Rábano A, Bermejo J, Martínez Pérez M, Guerrero MC, Contreras MA, Lunar A: Creutzfeldt-Jakob disease acquired via a dural graft: failure of therapy with quinacrine and chlorpromazine. Surg Neurol 2005; 64:542-545 (Pubitemid 41635236)
16. Clarke CE, Bamford JM, House A: Dyskinesia in Creutzfeldt-Jakob disease precipitated by antidepressant therapy. Mov Disord 1992; 7:86-87
17. Rabins PV, Mace NL, Lucas MJ: The impact of dementia on the family. JAMA 1982; 248:333-335 (Pubitemid 12070768)
18. Steele C, Rovner B, Chase GA, Folstein M: Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Am J Psychiatry 1990; 147:1049-1051 (Pubitemid 20257519)
19. Schneider LS, Dagerman K, Insel PS: Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 2006; 14:191-210
20. Schneider LS, Dagerman KS, Insel P: Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005; 294:1934-1943 (Pubitemid 41464695)
21. Banerjee S, Hellier J, Dewey M, Romeo R, Ballard C, Baldwin R, Bentham P, Fox C, Holmes C, Katona C, Knapp M, Lawton C, Lindesay J, Livingston G, McCrae N, Moniz-Cook E, Murray J, Nurock S, Orrell M, O'Brien J, Poppe M, Thomas A, Walwyn R, Wilson K, Burns A: Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet 2011; 378:403-411
22. Gill SS, Bronskill SE, Normand SLT, Anderson GM, Sykora K, LamK, Bell CM, Lee PE, Fischer HD, Herrmann N, Gurwitz JH, Rochon PA: Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med 2007; 146:775-786 (Pubitemid 351650498)
23. Aalten P, de Vugt ME, Lousberg R, Korten E, Jaspers N, Senden B, Jolles J, Verhey FRJ: Behavioral problems in dementia: a factor analysis of the Neuropsychiatric Inventory. Dement Geriatr Cogn Disord 2003; 15:99-105 (Pubitemid 36098763)
24. Spalletta G, Musicco M, Padovani A, Rozzini L, Perri R, Fadda L, Canonico V, Trequattrini A, Pettenati C, Caltagirone C, Palmer K: Neuropsychiatric symptoms and syndromes in a large cohort of newly diagnosed, untreated patients with Alzheimer disease. Am J Geriatr Psychiatry 2010; 18:1026-1035
25. Collinge J, Gorham M, Hudson F, Kennedy A, Keogh G, Pal S, Rossor M, Rudge P, Siddique D, Spyer M, Thomas D, Walker S, Webb T, Wroe S, Darbyshire J: Safety and efficacy of quinacrine in human prion disease (PRION-1 Study): a patient-preference trial. Lancet Neurol 2009; 8:334-344
26. Mead S, Ranopa M, Gopalakrishnan GS, Thompson AGB, Rudge P, Wroe S, Kennedy A, Hudson F, MacKay A, Darbyshire JH, Collinge J, Walker AS: PRION-1 scales analysis supports use of functional outcome measures in prion disease. Neurology 2011; 77:1674-1683
27. Thompson AG, Lowe J, Fox Z, Lukic A, Porter MC, Ford L, Gorham M, Gopalakrishnan GS, Rudge P, Walker AS, Collinge J, Mead S: The Medical Research Council Prion Disease Rating Scale: a new outcome measure for prion disease therapeutic trials developed and validated using systematic observational studies. Brain 2013; 136:1116-1127
28. Cooper SA, Murray KL, Heath CA, Will RG, Knight RS: Isolated visual symptoms at onset in sporadic Creutzfeldt-Jakob disease: the clinical phenotype of the "Heidenhain variant." Br J Ophthalmol 2005; 89:1341-1342 (Pubitemid 41638877)
29. McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, Cicin-Sain A, Ferrara R, Spiegel R: Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000; 356: 2031-2036 (Pubitemid 32009817)
30. Mori E, Ikeda M, Kosaka K; Donepezil-DLB Study Investigators: Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial. Ann Neurol 2012; 72:41-52
31. Schneeweiss S, Setoguchi S, Brookhart A, Dormuth C, Wang PS: Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ 2007; 176:627-632 (Pubitemid 46426056)